Vertex Sells INCIVO Product Royalty Rights to Janssen Pharmaceutica for $152M
November 20, 2013 at 05:46 AM EST
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) today announced that it has sold its product royalty rights relating to INCIVO® (telaprevir) to Janssen Pharmaceutica N.V. Under the agreement, Janssen
